TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Perseus Proteomics, Inc. ( (JP:4882) ) just unveiled an update.
Perseus Proteomics Inc. reported its financial results for the second quarter ending September 30, 2025, showing a slight increase in net sales compared to the previous year, but still operating at a loss. The company’s financial position has weakened, with a decrease in total assets and shareholders’ equity ratio, indicating ongoing financial challenges. Despite these setbacks, the company remains committed to its strategic goals, although it has not provided a financial forecast for the fiscal year ending March 31, 2026, citing difficulty in making rational predictions.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. is a company listed on the Tokyo Stock Exchange, specializing in proteomics, which involves the large-scale study of proteins, particularly their structures and functions. The company is focused on developing innovative solutions in the biotechnology sector, leveraging its expertise in protein research to address various market needs.
Average Trading Volume: 308,386
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.59B
For a thorough assessment of 4882 stock, go to TipRanks’ Stock Analysis page.